Expression of p53, glutathione S-transferase-π, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer

Journal of the National Cancer Institute

Volumn 89, Issue 9, 1997, Pages 639-645

  Silvestrini, Rosella ^a   Veneroni, Silvia ^a   Benini, Elvira ^a   Daidone, Maria Grazia ^a   Luisi, Antonella ^a   Leutner, Monica ^a   Maucione, Antonio ^a   Kenda, Rado ^a   Zucali, Roberto ^a   Veronesi, Umberto ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; GLUTATHIONE TRANSFERASE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; RECURRENCE RISK;

EID: 0030992313     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.9.639     Document Type: Article

References (42)

1. Clark GM. Do we really need prognostic factors for breast cancer? Breast Cancer Res Treat 1994;30:117-26.
2. Silvestrini R. Cell kinetics: prognostic and therapeutic implications in human tumours. Cell Prolif 1994;27:579-96.
3. Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 1992;10:1284-91.
4. Wright C, Nicholson S, Angus B, Sainsbury JR, Farndon J, Harris AL, et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992;65:118-21.
5. Veneroni S, Zaffaroni N, Daidone MG, Benini E, Villa R, Silvestrini R. Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. Eur J Cancer 1994;30A:1002-7.
6. Fuqua SA, Oesterreich S. Hilsenbeck SG, Von Hoff DD, Eckardt J, Osborne CK. Heat shock proteins and drug resistance. Breast Cancer Res Treat 1994;32:67-71.
7. Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P. et al. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 1996;14:1604-10.
8. Gasparini G, Barbareschi M, Doglioni C. Dalla Palma P, Mauri FA, Boracchi P, et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1995;1:189-98.
9. Elledge RM, Gray R, Mansour E, Yu Y, Clark GM, Ravdin P. et al. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 1995;87:1254-6.
10. Muss HB, Thor AD. Berry DA, Kute T, Liu ET, Koerner F, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer [published erratum appears in N Engl J Med 1994;331:211]. N Engl J Med 1994;330:1260-6.
11. Stal O, Sullivan S, Wingren S, Skoog L, Rutqvist LE, Carstensen JM, et al. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 1995;31A:2185-90.
12. Veronesi U, Banfi A, Salvadori B, Luini A, Saccozzi R, Zucali R, et al. Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized trial. Eur J Cancer 1990;26:668-70.
13. Jansson T, Inganas M, Sjogren S, Norberg T, Lindgren A, Holmberg L, et al. p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol 1995;13:2745-51.
14. Oren M. The involvement of oncogenes and tumor suppressor genes in the control of apoptosis. Cancer Metastasis Rev 1992;11:141-8.
15. Fan S, Smith ML, River DJ 2nd, Duba D, Zhan Q, Kohn KW, et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995;55: 1649-54.
16. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10.
17. Gilbert L, Elwood LJ, Merino M, Masood S, Barnes R, Steinberg SM, et al. A pilot study of pi-class glutathione 5-transferase expression in breast cancer: correlation with estrogen receptor expression and prognosis in node-negative breast cancer. J Clin Oncol 1993;11:49-58.
18. Veronesi U, Saccozzi R, Del Vecchio M, Banfi A, Clemente C, De Lena M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 1981;305:6-11.
19. 3H-thymidine labelling index in breast cancer. The SICCAB Group for Quality Control of Cell Kinetic Determination. Cell Prolif 1991; 21:437-45.
20. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, et al. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 1993;85:965-70.
21. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994;86: 499-504.
22. Daidone MG, Ricardi U, Veneroni S, Faranda A, Benini E, Urgesi A, et al. Biological predictors of response to radiotherapy in cervical carcinomas. Int J Oncol 1997;10:41-6.
23. Ronchi E, Granata G, Brivio M, Coradini D, Miodini P, Di Fronzo G. A double-labeling assay for simultaneous estimation and characterization of estrogen and progesterone receptors using radioiodinated estradiol and tritiated Org 2058. Tumori 1986;72:251-7.
24. Silvestrini R, Rao S, Benini E, Daidone MG, Pilotti S. Immunohistochemical detection of p53 in clinical breast cancers: a look at methodologic approaches [letter]. J Natl Cancer Inst 1995;87:1020.
25. Silvestrini R, Daidone MG, Luisi A, Boracchi P, Mezzetti M, Di Fronzo G, et al. Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol 1995;13:697-704.
26. 3H-Thymidine-labeling index as a prognostic indicator in node-positive breast cancer. J Clin Oncol 1990;8:1321-6.
27. Silvestrini R, Daidone MG, Mastore M, Di Fronzo G, Coradini D, Boracchi P, et al. Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy. J Clin Oncol 1993;11:1150-5.
28. Silvestrini R, Daidone MG, Faranda A, Benini E, Tomasic G, Boracchi P, et al. Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers. Clin Cancer Res 1996; 2:2007-13.
29. Frierson HF, Gaffey MJ, Meredith SD, Boyd JC, Williams ME. Immunohistochemical staining and Southern blot hybridization for glutathione S-transferase π in mammary infiltrating ductal carcinoma. Modem Pathol 1995;8:643-7.
30. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1994;69:135-9.
31. Battifora H. p53 immunohistochemistry: a word of caution [editorial]. Hum Pathol 1994; 25:435-7.
32. Jacobs TW, Prioleau JE, Stillman IE, Schnitt SJ. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 1996;88:1054-9.
33. Sierra A, Lloveras B, Castellsague X, Moreno L, Garcia-Ramirez M, Fabra A. Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma. Int J Cancer 1995;60:54-60.
34. Bellamy CO, Harrison DJ. Evaluation of glutathione S-transferase Pi in non-invasive ductal carcinoma of breast. Br J Cancer 1994;69: 183-5.
35. Soubeyran I, Quenel N, Mauriac L, Durand M, Bonichon F, Coindre JM. Variation of hormonal receptor, pS2, c-erb-2 and GSTπ contents in breast carcinomas under tamoxifen: a study of 74 cases. Br J Cancer 1996;73:735-43.
36. Wright C, Cairns J, Cantwell BJ, Cattan AR, Hall AG, Harris AL, et al. Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases. Br J Cancer 1992;65: 271-4.
37. Efferth T, Mattern J, Volm M. Immunohistochemical detection of P glycoprotein, glutathione S-transferase and DNA topoisomerase II in human tumors. Oncology 1992;49:368-75.
38. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 1992;11:121-39.
39. Sumantran VN, Ealovega MW, Nunez G, Clarke MG, Wicha MS. Overexpression of Bcl-xs sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res 1995; 55:2507-10.
40. Xia F, Wang X, Wang YH, Tsang NM, Yandell DW, Kelsey KT, et al. Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines. Cancer Res 1995;55:12-5.
41. Meister A, Anderson ME. Glutathione. Annu Rev Biochem 1983;52:711-60.
42. Peters WH, Roelofs HM, van Putten WL, Jansen JB, Klijn JG, Foekens JA. Response to adjuvant chemotherapy in primary breast cancer: no correlation with expression of glutathione S-transferases. Br J Cancer 1993;68:86-92.